EGFR and head and neck cancer: We recently reported that cetuximab, which inhibits the EGFR signaling pathway, can generate a DNA repair defect in head and neck cancer cells and subsequently induce a contextual synthetic lethality with the PARP inhibitor ABT-888 [11].